Sex differences in changes in prolactin levels and sexual function after switching from risperidone to paliperidone palmitate in schizophrenia
Tost, Meritxell (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Barbero, Juan David (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Montalvo, Itziar (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal)
González-Rodríguez, Alexandre (Universitat de Barcelona. Hospital Mútua de Terrassa)
Aguayo, Raquel (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Álvarez, Aida (Universitat de Barcelona. Hospital Mútua de Terrassa)
Gabernet, Rosa (Hospital de Mataró. Consorci Sanitari del Maresme)
Izquierdo, Eduard (Universitat de Barcelona. Hospital Mútua de Terrassa)
Merodio Ruiz, Igor (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Acebillo, Siddarta (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Palao, Diego (Universitat Autònoma de Barcelona. Departament de Psiquiatria i de Medicina Legal)
Labad, Javier (Hospital de Mataró. Consorci Sanitari del Maresme)

Date:	2024
Abstract:	Background and objectives: Hyperprolactinaemia is a significant side effect of antipsychotic medications and may cause sexual dysfunction. Although risperidone and paliperidone can induce prolactin elevation, previous studies suggest that switching from risperidone long-acting injectable (LAI) to paliperidone palmitate (PP) might reduce prolactin concentrations in early psychosis patients. We aimed to evaluate the effect of switching from risperidone to PP on sexual functionality and prolactin levels in patients with schizophrenia. Methods: We studied 38 patients with schizophrenia who were treated with risperidone (oral or R-LAI) monotherapy at stable doses for at least two months and had an indication to be switched to PP by their psychiatrists. Three assessments were completed: 1) baseline (preswitch), 2) 3 months post-switch, and 3) 6 months post-switch. Prolactin concentrations in plasma were determined. Sexual functioning was assessed with the Arizona Sexual Experience Scale (ASEX). Statistical analyses were conducted in 27 patients who had at least one follow-up visit. Longitudinal changes in prolactin levels and sexual function after switching from risperidone to PP were analysed with linear mixed models. Significance was set at p < 0. 05. Results: Prolactin concentrations were reduced in women after the switch, with a significant time by sex effect (p = 0. 035). Antipsychotic doses influenced prolactin levels (p = 0. 006), such that higher antipsychotic doses were associated with higher prolactin concentrations. No significant differences were found in ASEX total scores at 6 months after the switch. Conclusions: In patients with schizophrenia, switching from risperidone to PP was associated with a reduction in prolactin concentrations in women but not men.
Rights:	Aquest material està protegit per drets d'autor i/o drets afins. Podeu utilitzar aquest material en funció del que permet la legislació de drets d'autor i drets afins d'aplicació al vostre cas. Per a d'altres usos heu d'obtenir permís del(s) titular(s) de drets.
Language:	Anglès
Document:	Article ; recerca ; Versió acceptada per publicar
Subject:	Prolactin ; Risperidone ; Paliperidone palmitate ; Sexual dysfunction ; Sex differences
Published in:	European Journal of Psychiatry, Vol. 38, Núm. 3 (July 2024) , ISSN 0213-6163

DOI: 10.1016/j.ejpsy.2024.100259

Postprint 22 p, 479.9 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Parc Taulí Research and Innovation Institute (I3PT
Articles > Research articles
Articles > Published articles